English
 
My Account  

REGISTER & SECURE BENEFITS

  • View prices & discounts
  • Free gifts
  • Request & accept offers online
LOGIN NOW Not yet registered? Create your free account here!
Comparison

Metformin (hydrochloride) European Partner

Item no. HY-17471A-100mg
Manufacturer MedChem Express
CASRN 1115-70-4
Amount 100 mg
Category
Type Inhibitors
Specific against other
Purity 99.98
Citations [1]Soraya H, et al. Acute treatment with metformin improves cardiac function following NSC 37745 induced myocardial infarction in rats. Pharmacol Rep. 2012;64(6):1476-84.|[2]Xue J, et al. Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis. Reproduction. 2013 Aug 21;146(4):397-406.|[3]Otto M, et al. Metformin inhibits glycogen synthesis and gluconeogenesis in cultured rat hepatocytes. Diabetes Obes Metab. 2003 May;5(3):189-94.|[4]Avci CB, et al. Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev. 2013;14(2):765-8.|[5]Quaile MP, et al. Toxicity and toxicokinetics of metformin in rats. Toxicol Appl Pharmacol. 2010 Mar 15;243(3):340-7.|[6]Abdel-Zaher AO, et al. Novel mechanistic insights of the potential role of gasotransmitters and autophagy in the protective effect of metformin against hepatic ischemia/reperfusion injury in rats. Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb 6.|[7]Liu J, et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol. 2013 Feb;31(2):264-70.
Acta Biochim Biophys Sin (Shanghai). 2021 Mar 2;53(3):333-341.
Adv Mater. 2020 Nov;32(45):e2003708.
Andrology. 2020 May;8(3):663-670.
Arch Toxicol. 2019 Jun;93(6):1697-1712. 
Biochem Pharmacol. 2017 Aug 15:138:49-60.
Biomaterials. 2021 Jul:274:120850.
Biomed Pharmacother. 2019 Jul:115:108875.
Biomed Pharmacother. 2024 Sep 6:179:117399.
bioRxiv. 2025 Aug 26.
bioRxiv. 2025 March 25.
bioRxiv. 2025 May 31.
Bone Res. 2023 Aug 16;11(1):45.
Brain Res Bull. 2020 Nov;164:146-156.
Cancer Cell. 2020 Sep 14;38(3):350-365.e7.
Cancers (Basel). 2021 Aug 6;13(16):3978.
Cancers (Basel). 2022 Mar 17;14(6):1538.
Cell Death Dis. 2021 Oct 2;12(10):902.
Cell Death Dis. 2021 Oct 9;12(10):925.
Cell Metab. 2023 Jan 3;35(1):101-117.e11.
Cell Metab. 2023 Jul 11;35(7):1132-1146.e9.
Cell Physiol Biochem. 2017;44(4):1381-1395.
Cell Physiol Biochem. 2018;51(4):1566-1583.
Cell Rep. 2019 Oct. 
Cell Stem Cell. 2024 Jan 4;31(1):52-70.e8.
Chin Med J (Engl). 2025 Jun 16.
Dissolut Technol. 2020, 27(1):36-44.
EMBO Rep. 2022 Jun 7;23(6):e54147.
Endocrinology. 2018 May 1;159(5):2008-2021.
Eur J Oral Sci. 2025 Jan 8:e13034.
Eur J Pharmacol. 2025 Sep 15:1003:177900.
Exp Mol Med. 2019 May 22;51(5):1-14.
Front Bioeng Biotechnol. 2022 Mar 17;10:826093.
Front Pharmacol. 2016 Oct 20:7:390.
Front Pharmacol. 2020 Jul 31;11:1038.
iScience. 2023 Jan 25;26(4):106057.
J Biol Chem. 2020 Apr 3;295(14):4451-4463.
J Cell Mol Med. 2017 Dec;21(12):3322-3336.
J Cell Mol Med. 2019 Sep;23(9):6048-6059.
J Neuroinflammation. 2022 Jan 29;19(1):25.
Life Sci. 2019 Sep 1:232:116622.
Mech Ageing Dev. 2020 Oct;191:111347.
Mol Cell Proteomics. 2017 Jul;16(7):1324-1334.
Mol Neurobiol. 2017 Jul;54(5):3327-3341.
Mol Oncol. 2017 Aug;11(8):1035-1049.
Mol Oncol. 2017 Oct;11(10):1475-1492.
Nat Commun. 2025 Nov 28;16(1):10751.
Nat Commun. 2019 Feb 6;10(1):620.
Nat Metab. 2025 Apr;7(4):730-741.
Nature. 2023 Sep;621(7977):188-195.
Neuropharmacology. 2020 Mar 15;165:107816.
Onco Targets Ther. 2020 May 4;13:3777-3788.
Patent. US20210128693A1.
Patent. US20240358802A1
Patent. US20240358802A1.
Pathogens. 2021 Mar 2;10(3):283.
Pharmaceuticals (Basel). 2024 Sep 19;17(9):1234.
Phytother Res. 2024 May 10.
Redox Biol. 2023 Aug:64:102786.
Research Square Preprint. 2022 Jan.
Research Square Preprint. 2023 Jul 24.
Sci Rep. 2025 Apr 2;15(1):11309.
Signal Transduct Target Ther. 2020 May 20;5(1):56.
Signal Transduct Target Ther. 2023 Mar 6;8(1):95.
Spine. 2019 Aug 1;44(15):E865-E872.
Transl Stroke Res. 2023 Jun;14(3):364-382.
Virus Res. 2023 Aug:333:199139.
Acta Pharm Sin B. 2025 Sep 19.
Acta Pharmacol Sin. 2022 Jun;43(6):1360-1371.
Am J Physiol Cell Physiol. 2024 Jun 1;326(6):C1590-C1603.
Ann Transl Med. 2021 Oct;9(20):1547.
Antioxidants. 2020 Oct 28;9(11):1057.
Aquaculture. 2024 Dec 15.
Arch Biochem Biophys. 2022 Jun 15;722:109216.
Autophagy. 2025 Nov 30:1-21.
Biochem Bioph Res Co. 2020 Dec 17;533(4):665-671.
Biochem Cell Biol. 2023 Dec 1;101(6):523-530.
Biochem Pharmacol. 2023 Sep:215:115636.
Biochim Biophys Acta Mol Cell Biol Lipids. 2025 May 12:159628.
Biofactors. 2023 Jul-Aug;49(4):831-848.
Biomaterials. 2025 Aug:319:123210.
Biomedicines. 2024 Nov 4;12(11):2526.
Biomolecules. 2022 Mar 9;12(3):422.
Biomolecules. 2025 Apr 9;15(4):556.
bioRxiv. 2023 May 12.
bioRxiv. 2025 Aug 25:2025.08.21.671520.
bioRxiv. 2025 March 21.
bioRxiv. 2025 May 05.
Bone. 2025 Jan 28:193:117411.
Brain Behav Immun. 2024 Jun 6:S0889-1591(24)00445-8.
Breast Cancer Res Treat. 2025 Jun;211(2):467-478.
Cancer Cell Int. 2024 Feb 14;24(1):74.
Cancer Lett. 2022 Apr 28:532:215582.
Cancer Lett. 2024 Apr 10:587:216732.
Cancer Lett. 2024 Aug 21:217177.
Cancer Rep (Hoboken). 2025 Jul;8(7):e70245.
Cell Biochem Biophys. 2025 Apr 4.
Cell Commun Signal. 2023 May 4;21(1):99.
Cell Death Differ. 2023 Jul;30(7):1829-1848.
Cell Death Dis. 2022 Apr 20;13(4):384.
Cell Mol Life Sci. 2023 Sep 9;80(10):283.
Cell Regen. 2022 May 5;11(1):19.
Cell Rep Med. 2025 Jul 15;6(7):102211.
Cell Rep. 2022 Nov 22;41(8):111707.
Cell Res. 2023 Dec;33(12):904-922.
Cell Signal. 2024 Jun:118:111125.
Chin Med. 2025 Nov 17;20(1):190.
Circulation. 2023 Jan 10;147(2):158-174.
Clinical Cancer Drugs. 2020 Apr.
Curr Issues Mol Biol. 2025 Jul 3;47(7):515.
Emerg Microbes Infect. 2022 Dec;11(1):815-828.
Environ Toxicol. 2021 Dec;36(12):2414-2425.
Environ Toxicol. 2024 Apr;39(4):2452-2465.
Eur J Pharmacol. 2023 Mar 15:943:175569.
Eur J Pharmacol. 2023 Oct 5:956:175942.
Food Res Int. 2025 Jun:211:116502.
Free Radic Biol Med. 2025 Sep:237:503-514.
Front Immunol. 2016 Dec 12:7:597.
Front Oncol. 2021 Nov 22;11:762523.
Genes (Basel). 2022 Dec 16;13(12):2384.
Genes Dis. 2025 Sep 10.
Hum Reprod. 2020 May 1;35(5):1145-1158.
Int Immunopharmacol. 2023 Sep 15;124(Pt A):110905.
Int Immunopharmacol. 2025 May 20:159:114897.
Int J Biol Macromol. 2025 Aug 21;323(Pt 1):147047.
Int J Mol Sci. 2022 Dec 25;24(1):343.
Int J Morphol. 40(5):1152-1164, 2022.
iScience. 2025 Apr 3;28(5):112344.
J Adv Res. 2024 Apr 14:S2090-1232(24)00155-3.
J Adv Res. 2025 Mar 10:S2090-1232(25)00174-2.
J Cell Physiol. 2025 Nov;240(11):e70110.
J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Dec 28:1252:124446.
J Drug Target. 2025 Jul 17:1-10.
J Ethnopharmacol. 2026 Feb 28:357:120941.
J Food Meas Charact. 2025 Sep 1.
J Inflamm (Lond). 2024 Jul 9;21(1):25.
J Inflamm Res. 2025 Mar 19:18:4087-4101.
J Med Chem. 2022 Sep 8;65(17):11818-11839.
J Nanobiotechnology. 2025 Oct 14;23(1):670.
J Neuropathol Exp Neurol. 2025 Aug 19:nlaf092.
J Orthop Surg Res. 2023 Nov 4;18(1):831.
J Virol. 2025 Aug 29:e0052925.
Liver Int. 2023 Jul;43(7):1577-1592.
Mol Cell Endocrinol. 2024 Mar 1:582:112140.
Mol Med Rep. 2023 Jan;27(1):17.
Mol Reprod Dev. 2024 Aug;91(8):e23768.
Nat Commun. 2021 Aug 24;12(1):5106.
Nature. 2025 Feb;638(8052):1112-1121.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 4.
Neuroscience. 2025 Jan 26:565:91-98.
Onco Targets Ther. 2020 May 19;13:4445-4455.
Oncol Lett. 2021 Jan;21(1):31.
Oral Dis. 2025 Feb;31(2):468-481.
Phytomedicine. 2024 Apr 24:129:155679.
Phytomedicine. 2025 Nov 27:150:157628.
PLoS Biol. 2025 Nov 24;23(11):e3003490.
PLoS One. 2023 May 18;18(5):e0283943.
PLoS Pathog. 2023 Feb 3;19(2):e1011126.
PLoS Pathog. 2024 Jun 21;20(6):e1012305.
Probiotics Antimicrob Proteins. 2025 Nov 26.
Protein Cell. 2022 Nov;13(11):825-841.
Res Sq. 2024 Jul 12.
Res Sq. 2025 Jul 13.
Research Square Preprint. 2020 Dec.
Research Square Print. 2022 Aug.
Research Square Print. November 29th, 2022.
Rev Bras Farmacogn. 2025 Sep 4.
Rheumatology (Oxford). 2023 Apr 3;62(4):1652-1661.
Sci Adv. 2025 May 16;11(20):eadq3870.
Sci Rep. 2025 Jul 26;15(1):27294.
Sci Total Environ. 2024 Feb 20:912:169496.
Small Methods. 2020, 2000483.
SSRN. 2023 Feb 27.
SSRN. 2024 May 30.
SSRN. 2025 Jan 31.
SSRN. 2025 Jul 8.
SSRN. 2025 Oct 14.
Stem Cell Res Ther. 2025 Apr 18;16(1):186.
Stem Cell Res Ther. 2025 Jan 23;16(1):20.
Stem Cells Dev. 2021 Oct 15;30(20):1017-1027.
University of Otago. 2025 Oct 7.
Virus Genes. 2022 Apr;58(2):133-142.
Smiles NC(NC(N(C)C)=N)=N.Cl
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias 1,1-Dimethylbiguanide (hydrochloride)
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound1
Manufacturer - Applications
Cancer-Kinase/protease
Manufacturer - Category
Reference compound / Active compounds; API
Manufacturer - HS Code
H302, H315, H319, H335
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Product Description
Metformin (1, 1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo[1][2][3][4][5][6][7].
Manufacturer - Research Area
Metabolic Disease; Cardiovascular Disease; Cancer
Solubility
DMSO : ≥ 1.7 mg/mL|H2O : ≥ 100 mg/mL
Manufacturer - Pathway
Apoptosis; Autophagy; Epigenetics; PI3K/Akt/mTOR
Clinical information
Launched
Isoform
AMPK
UNSPSC Code
12352211
Precautionary
H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?

sales@hoelzel.de

 

« Back

Contact

Hölzel Diagnostika Handels GmbH
Weinsbergstr 118a
50823 Cologne
Germany

T +49 221 126 02 66
F +49 221 126 02 67

info@hoelzel.de

About Hölzel
Service
Infodesk
Spendenaktion Datenschutzsiegel

Copyright 2025 Hölzel Diagnostika Handels GmbH

To top